John C. Martin (businessman)

John Charles Martin
Born	(1951-05-07) 7 May 1951 Easton, Pennsylvania, United States
Died	30 March 2021(2021-03-30) (aged 69) Palo Alto, California, United States
Occupation(s)	Entrepreneur, Biotechnologist, CEO
Years active	1978–2018
Known for	CEO of Gilead Sciences; development of antiviral drugs Atripla and Sovaldi

John Charles Martin (May 7, 1951 – March 30, 2021) was an American billionaire entrepreneur who served as the chief executive officer of the biotechnology firm Gilead Sciences from 1996 until 2016, and subsequently as its executive chairman from 2016 to 2018. He began his tenure at Gilead Sciences in 1990, initially appointed as vice president of research and development. The company gained recognition for producing essential antiviral medications, including Atripla for HIV/AIDS and marketing Sovaldi (sofosbuvir) to treat hepatitis C. Martin's contributions earned him numerous accolades, notably the Biotechnology Heritage Award in 2017.

Education

Martin completed his undergraduate studies in chemical engineering at Purdue University. He further obtained an MBA specializing in marketing from Golden Gate University and earned a doctorate in organic chemistry from the University of Chicago. Additionally, he held positions on the boards of trustees at both Golden Gate University and the University of Chicago.

Syntex Corporation

Between 1978 and 1984, Martin was employed by Syntex Corporation.

Bristol-Myers Squibb

From 1984 until 1990, he acted as director of antiviral chemistry at Bristol-Myers Squibb.

Gilead Sciences Inc

Martin joined Gilead Sciences, a U.S.-based biotechnology enterprise, in 1990 as vice president overseeing research and development. He ascended to CEO in 1996, assumed the role of chairman in May 2008, and transitioned to executive chairman in 2016.

During his leadership at Gilead, Martin played a pivotal role in creating Atripla, an innovative single-pill regimen that combined Gilead’s Truvada (tenofovir and emtricitabine) with Bristol-Myers Squibb’s Sustiva (efavirenz). Prior to this combination, Truvada and Sustiva were the most frequently prescribed antiretroviral drugs for HIV/AIDS in the United States. The introduction of Atripla enhanced patient compliance and mitigated the emergence of drug-resistant HIV strains. Collaboration between the two companies on this product commenced in 2004, culminating in FDA approval on July 12, 2006. Atripla was incorporated into the President's Emergency Plan for AIDS Relief (PEPFAR), and by 2011 Gilead commanded roughly half of the U.S. market for HIV medications.

In 2014, Martin spearheaded the launch of Sovaldi (sofosbuvir), a hepatitis C therapy that achieves a cure rate near 90% and generated $12 billion in revenue during its inaugural year. He is credited with rapidly elevating Sovaldi to blockbuster status, with profits surpassing $10 billion that year. Nevertheless, the $84,000 price tag per treatment course attracted criticism from U.S. legislators concerned about affordability for economically disadvantaged patients and government-funded health programs.

Sofosbuvir illustrates both the advantages and difficulties associated with specialty pharmaceuticals: it delivers superior efficacy and better patient tolerance compared to alternative treatments but carries high expenses that can limit patient access. Despite debate and congressional scrutiny, sofosbuvir quickly became one of the leading specialty drugs sold within the United States.

Global Health Contributions

Under John Martin’s guidance, access to HIV and hepatitis treatments worldwide was expanded through voluntary licensing agreements that facilitated generic production at reduced costs. His leadership ensured that Gilead’s medicines were incorporated into major international health initiatives such as PEPFAR and the Global Fund, significantly improving availability in low-income nations. Furthermore, he promoted broader access to hepatitis C therapies by negotiating licensing arrangements that lowered prices in developing countries heavily impacted by these diseases, including nations like Egypt and the Republic of Georgia.

Appointments

Martin held the position of president at the International Society for Antiviral Research from 1998 to 2000. He also served as chairman of the California Healthcare Institute during 2005–2006 and again in 2009, as well as chairing BayBio between 1999 and 2001.

Within the Federal government of the United States, Martin contributed in multiple capacities. He was a council member of the National Institute of Allergy and Infectious Diseases from 2000 to 2003, participated on the Centers for Disease Control and Prevention/Health Resources and Services Administration Advisory Committee focused on HIV and STD Prevention and Treatment between 2004 and 2007, and served on the Presidential Advisory Council on HIV/AIDS from 2006 through 2009.

In May 2018, he was appointed to the board of directors at The Scripps Research Institute.

Awards

In recognition of his work applying carbohydrate chemistry to biologically active nucleosides and nucleotides, Martin was honored with the American Chemical Society Isbell Award in 1990.

The International Society for Antiviral Research presented him with the Gertrude B. Elion Award for Scientific Excellence in 2003. That same year, he was also named a National Finalist for the EY Entrepreneur of the Year Award.

Martin was inducted into the National Academy of Engineering in 2008, acknowledged for his pioneering efforts in inventing, developing, and commercializing antiviral drugs, particularly those targeting HIV/AIDS.

The Institute of Human Virology at the University of Maryland School of Medicine granted him their Lifetime Achievement Award for Public Service in 2014, honoring his role in advancing anti-HIV medications and promoting AIDS prevention strategies such as Pre-exposure prophylaxis.

Under Martin’s leadership since 1996, Gilead Sciences experienced a remarkable increase in stock value, including a 157% rise between 2013 and 2015. For this achievement, Morningstar recognized him as the best CEO in 2015.

In 2017, he received the Biotechnology Heritage Award, jointly bestowed by the Biotechnology Innovation Organization and the Chemical Heritage Foundation.

His influential contributions to human health, especially in HIV/AIDS therapies, were further acknowledged with the NAS Award for Chemistry in Service to Society in 2019.

Personal life

Martin was divorced. He passed away on March 30, 2021, at a hospital in Palo Alto due to head trauma sustained from a fall.

As of April 2021, Forbes estimated his net worth at approximately $1.1 billion.

External links

• “Pandemic Perspectives with John C. Martin”, podcast interview by the Science History Institute, May 5, 2020.